Key result
Antidepressants were superior to placebo for decreasing Hamilton Depression Rating Scale scores in patients with CAD and depression (WMD 1.41; 95% CI 0.53-2.29; P=0.002).
Why the study?
Do antidepressants improve depression scores in patients with coronary artery disease and depression?
Population
798 subjects with documented coronary artery disease and meeting DSM-IV criteria for depression
Comparison
Antidepressants for 9 to 24 weeks vs Placebo
Design
Meta-analysis, randomized, double-blind
Follow-up
9 to 24 weeks
Authors
Loading...
Supports antidepressant use for depression in CAD; confirms efficacy and strengthens evidence for clinical adoption.
Meta-Analysis (n=798)
Double-blind
randomized
Do antidepressants improve depression scores in patients with coronary artery disease and depression?
Effect estimate: WMD 1.41 (95% CI 0.53-2.29)
p-value: p=0.002
Antidepressants are effective and well-tolerated for treating depression in patients with coronary artery disease.
Dowlati et al. (2010) conducted a meta-analysis in Depression in Coronary Artery Disease (n=798). Antidepressants (mirtazapine, citalopram, fluoxetine, and sertraline) vs. Placebo was evaluated on Hamilton Depression Rating Scale (HDRS) scores (WMD 1.41, 95% CI 0.53-2.29, p=0.002). Antidepressants were superior to placebo for decreasing Hamilton Depression Rating Scale scores in patients with CAD and depression (WMD 1.41; 95% CI 0.53-2.29; P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: